MPLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
MapLight Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.00+0.30 (+3.90%)
Close on Oct 19, 2026
- Market cap
- $363.45M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
56.6%
26M of 46M shares
Institutional holders
106
37 new, 10 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
12 buys · 139 sales
Net bought $145.75M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Forbion Growth III Management B.V. | 3,226,400 | 7.10% | 13G (passive) | Dec 31, 2025 |
| T. Rowe Price Investment Management, Inc. | 3,137,558 | 7.40% | 13G (passive) amendment | Mar 31, 2026 |
| Nan Fung Group Holdings Limited | 2,915,874 | 5.50% | 13G (passive) | Aug 13, 2026 |
| Catalyst4, Inc. | 27,536,011 | 49.90% | 13D (active) amendment | Aug 14, 2026 |
| Mark Vorsatz | 19,697,464 | 45.10% | 13D (active) | Oct 28, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MPLT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Novo Holdings A/S | 3,686,622 | 7.95% | $132.13M | – | 7.67% |
| Fcpm Iii Services B.V. | 3,226,400 | 6.96% | $115.63M | – | 15.41% |
| T. Rowe Price Investment Management, Inc. | 2,781,728 | 6.00% | $99.70K | −20,209 | 0.07% |
| Goldman Sachs Group Inc | 1,948,312 | 4.20% | $69.83M | −46,561 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,422,935 | 3.07% | $51.00K | +1,310,227 | 0.01% |
| BlackRock, Inc. | 1,025,134 | 2.21% | $36.74M | −314,597 | 0.00% |
| Nan Fung Group Holdings Ltd | 971,253 | 2.09% | $34.81M | – | 26.47% |
| 5AM Venture Management, LLC | 950,011 | 2.05% | $34.05M | – | 11.83% |
| Sanofi | 912,041 | 1.97% | $32.69M | – | 6.12% |
| State Street Corp | 852,150 | 1.84% | $30.54M | +513,034 | 0.00% |
| FMR LLC | 823,556 | 1.78% | $29.52M | +619,055 | 0.00% |
| Vanguard Capital Management LLC | 784,150 | 1.69% | $28.10M | +64,330 | 0.00% |
| Blue Owl Capital Holdings LP | 729,929 | 1.57% | $26.16M | −276,000 | 3.94% |
| Paradigm Biocapital Advisors LP | 685,852 | 1.48% | $24.58M | New | 0.46% |
| Pivotal bioVenture Partners Investment Advisor LLC | 611,446 | 1.32% | $21.91M | −1 | 7.12% |
| Velan Capital Investment Management LP | 492,893 | 1.06% | $17.67M | – | 10.76% |
| Siren, L.L.C. | 450,000 | 0.97% | $16.13M | – | 0.33% |
| Capital World Investors | 415,730 | 0.90% | $14.90M | New | 0.00% |
| Geode Capital Management, LLC | 402,051 | 0.87% | $14.41M | −79,150 | 0.00% |
| Baker Bros. Advisors LP | 364,705 | 0.79% | $13.07M | – | 0.07% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 106 | 26M | 56.6% | 37 / 21 | 30 / 10 | 4M | 3M |
| Q1 2026 | 81 | 25M | 53.5% | 22 / 26 | 14 / 14 | 4M | 4M |
| Q4 2025 | 74 | 26M | 55.8% | 74 / 0 | 0 / 0 | 26M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MPLT | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 625,046 | 1.35% | $22.40M | 0.24% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 605,601 | 1.31% | $21.70M | 0.21% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 552,279 | 1.19% | $19.79M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 498,428 | 1.07% | $17.86M | 0.17% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 406,402 | 0.88% | $5.29M | 0.07% | Jul 31, 2026 |
| SMALLCAP World Fund Inc | 404,389 | 0.87% | $14.49M | 0.02% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 402,792 | 0.87% | $14.44M | 0.15% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 398,809 | 0.86% | $14.29M | 0.10% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 342,343 | 0.74% | $12.27M | 0.24% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 267,770 | 0.58% | $9.60M | 0.01% | Jun 30, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 263,529 | 0.57% | $3.43M | 0.07% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 216,312 | 0.47% | $7.75M | 0.01% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 202,900 | 0.44% | $2.64M | 0.12% | Jul 31, 2026 |
| Fidelity Series Small Cap Core Fund | 138,400 | 0.30% | $1.80M | 0.11% | Jul 31, 2026 |
| Vanguard Explorer Fund | 131,368 | 0.28% | $1.71M | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christopher A. Kroeger | Chief Executive Officer, Director | 1,370,790 | 2.96% | Aug 19, 2026 |
| Kristopher Hanson | General Counsel | 137,044 | 0.30% | Sep 18, 2026 |
| Jonathan Gillis | CAO and Interim CFO | 152,482 | 0.33% | Aug 19, 2026 |
| Erin Pennock Foff | Chief Medical Officer | 312,261 | 0.67% | Aug 19, 2026 |
| James Woodruff Lillie | Chief Scientific Officer | 210,110 | 0.45% | Aug 19, 2026 |
| Anatol Kreitzer | Chief Discovery Officer | 180,926 | 0.39% | Aug 19, 2026 |
| Vishwas Setia | Chief Financial Officer | 356,256 | 0.77% | May 6, 2026 |
| Troy Cox | Director | 23,484 | 0.05% | Jul 28, 2026 |
| George Pavlov | Director | 28,932 | 0.06% | Jun 25, 2026 |
| Martin Babler | Director | 7,864 | 0.02% | Jun 25, 2026 |
| Maria C. Walker | Director | 62,703 | 0.14% | Jun 25, 2026 |
| Timothy John Garnett | Director | 67,581 | 0.15% | Jun 25, 2026 |
| Nanna Liebach Luneborg | Director | 3,932 | 0.01% | Jun 25, 2026 |
| Robert C. Malenka | Director | 348,138 | 0.75% | Apr 17, 2026 |
| James D. Trenkle | Director | – | – | Oct 27, 2025 |
| Catalyst4, Inc. | 10% owner | 25,306,689 | 54.57% | Aug 18, 2026 |
| Holdings A/S Novo | 10% owner | 2,733,681 | 5.89% | Oct 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kristopher Hanson General Counsel | Sep 16, 2026 | Sale(10b5-1 plan) | −16,509 | $11.67 | $192.66K | 137,044 |
| Kristopher Hanson General Counsel | Aug 17, 2026 | Award | +7,730 | – | – | 153,553 |
| Christopher A. Kroeger Chief Executive Officer, Director | Aug 17, 2026 | Award | +23,145 | – | – | 1,269,600 |
| Erin Pennock Foff Chief Medical Officer | Aug 17, 2026 | Award | +13,360 | – | – | 312,261 |
| James Woodruff Lillie Chief Scientific Officer | Aug 17, 2026 | Award | +7,730 | – | – | 210,110 |
| Anatol Kreitzer Chief Discovery Officer | Aug 17, 2026 | Award | +6,020 | – | – | 180,926 |
| Jonathan Gillis CAO and Interim CFO | Aug 17, 2026 | Award | +2,222 | – | – | 152,482 |
| Jonathan Gillis CAO and Interim CFO | Aug 17, 2026 | Award | +6,020 | – | – | 150,260 |
| Catalyst4, Inc. 10% owner | Aug 14, 2026 | Buy | +4,400,000 | $11.38 | $50.07M | 25,306,689 |
| James Woodruff Lillie Chief Scientific Officer | Aug 3, 2026 | Sale(10b5-1 plan) | −22,082 | $12.54 | $276.91K | 202,380 |
| Catalyst4, Inc. 10% owner | Jul 30, 2026 | Buy | +1,000,000 | $13.00 | $13.00M | 20,906,689 |
| Catalyst4, Inc. 10% owner | Jul 29, 2026 | Buy | +3,000 | $12.63 | $37.89K | 19,906,689 |
| Catalyst4, Inc. 10% owner | Jul 28, 2026 | Buy | +141,088 | $10.74 | $1.52M | 19,838,552 |
| Catalyst4, Inc. 10% owner | Jul 28, 2026 | Buy | +65,137 | $11.69 | $761.45K | 19,903,689 |
| Troy Cox Director | Jul 28, 2026 | Buy | +15,620 | $9.52 | $148.70K | 15,620 |
| Jonathan Gillis CAO and Interim CFO | Jul 17, 2026 | Sale(10b5-1 plan) | −900 | $38.17 | $34.35K | 144,240 |
| Jonathan Gillis CAO and Interim CFO | Jul 17, 2026 | Sale(10b5-1 plan) | −600 | $36.51 | $21.91K | 162,109 |
| Jonathan Gillis CAO and Interim CFO | Jul 17, 2026 | Sale(10b5-1 plan) | −16,969 | $37.61 | $638.20K | 145,140 |
| Anatol Kreitzer Chief Discovery Officer | Jul 17, 2026 | Sale(10b5-1 plan) | −2,833 | $37.05 | $104.96K | 189,246 |
| Anatol Kreitzer Chief Discovery Officer | Jul 17, 2026 | Sale(10b5-1 plan) | −14,140 | $37.70 | $533.08K | 175,106 |
| Anatol Kreitzer Chief Discovery Officer | Jul 17, 2026 | Sale(10b5-1 plan) | −200 | $38.39 | $7.68K | 174,906 |
| James Woodruff Lillie Chief Scientific Officer | Jul 17, 2026 | Sale | −2,077 | $37.90 | $78.72K | 224,462 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 17, 2026 | Sale | −16,779 | $37.90 | $635.92K | 1,246,455 |
| Kristopher Hanson General Counsel | Jul 17, 2026 | Sale | −1,130 | $37.90 | $42.83K | 145,823 |
| Erin Pennock Foff Chief Medical Officer | Jul 17, 2026 | Sale(10b5-1 plan) | −3,656 | $37.90 | $138.56K | 298,901 |
| Jonathan Gillis CAO and Interim CFO | Jul 16, 2026 | Sale(10b5-1 plan) | −1,476 | $37.44 | $55.26K | 162,709 |
| Jonathan Gillis CAO and Interim CFO | Jul 16, 2026 | Sale(10b5-1 plan) | −6,979 | $36.66 | $255.85K | 164,185 |
| Anatol Kreitzer Chief Discovery Officer | Jul 16, 2026 | Sale(10b5-1 plan) | −7,464 | $36.66 | $273.63K | 193,671 |
| Anatol Kreitzer Chief Discovery Officer | Jul 16, 2026 | Sale(10b5-1 plan) | −1,592 | $37.44 | $59.60K | 192,079 |
| James Woodruff Lillie Chief Scientific Officer | Jul 16, 2026 | Sale | −5,009 | $36.45 | $182.58K | 230,077 |
| James Woodruff Lillie Chief Scientific Officer | Jul 16, 2026 | Sale | −3,526 | $37.26 | $131.38K | 226,551 |
| James Woodruff Lillie Chief Scientific Officer | Jul 16, 2026 | Sale | −12 | $37.96 | $456 | 226,539 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 16, 2026 | Sale | −40,899 | $36.46 | $1.49M | 1,291,417 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 16, 2026 | Sale | −92 | $37.96 | $3.49K | 1,263,234 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 16, 2026 | Sale | −28,091 | $37.26 | $1.05M | 1,263,326 |
| Kristopher Hanson General Counsel | Jul 16, 2026 | Sale | −11 | $37.96 | $418 | 146,953 |
| Kristopher Hanson General Counsel | Jul 16, 2026 | Sale | −4,776 | $36.45 | $174.09K | 150,295 |
| Kristopher Hanson General Counsel | Jul 16, 2026 | Sale | −3,331 | $37.26 | $124.11K | 146,964 |
| Erin Pennock Foff Chief Medical Officer | Jul 16, 2026 | Sale(10b5-1 plan) | −9,163 | $36.46 | $334.08K | 308,441 |
| Erin Pennock Foff Chief Medical Officer | Jul 16, 2026 | Sale(10b5-1 plan) | −5,865 | $37.26 | $218.53K | 302,576 |
| Erin Pennock Foff Chief Medical Officer | Jul 16, 2026 | Sale(10b5-1 plan) | −19 | $37.96 | $721 | 302,557 |
| Jonathan Gillis CAO and Interim CFO | Jul 15, 2026 | Sale(10b5-1 plan) | −4,699 | $36.94 | $173.58K | 171,164 |
| Jonathan Gillis CAO and Interim CFO | Jul 15, 2026 | Sale(10b5-1 plan) | −5,356 | $36.13 | $193.51K | 175,863 |
| Anatol Kreitzer Chief Discovery Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −5,545 | $36.13 | $200.34K | 205,645 |
| Anatol Kreitzer Chief Discovery Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −4,510 | $36.94 | $166.60K | 201,135 |
| James Woodruff Lillie Chief Scientific Officer | Jul 15, 2026 | Sale | −2,238 | $36.00 | $80.57K | 240,491 |
| James Woodruff Lillie Chief Scientific Officer | Jul 15, 2026 | Sale | −12 | $37.54 | $450 | 235,086 |
| James Woodruff Lillie Chief Scientific Officer | Jul 15, 2026 | Sale | −5,393 | $36.99 | $199.49K | 235,098 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 15, 2026 | Sale | −90 | $37.54 | $3.38K | 1,332,316 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 15, 2026 | Sale | −42,738 | $36.99 | $1.58M | 1,332,406 |
| Christopher A. Kroeger Chief Executive Officer, Director | Jul 15, 2026 | Sale | −18,950 | $36.00 | $682.20K | 1,375,144 |
| Kristopher Hanson General Counsel | Jul 15, 2026 | Sale | −10 | $37.54 | $375 | 155,071 |
| Kristopher Hanson General Counsel | Jul 15, 2026 | Sale | −2,147 | $36.00 | $77.29K | 160,184 |
| Kristopher Hanson General Counsel | Jul 15, 2026 | Sale | −5,103 | $36.99 | $188.76K | 155,081 |
| Erin Pennock Foff Chief Medical Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −18 | $37.54 | $676 | 317,604 |
| Erin Pennock Foff Chief Medical Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −7,155 | $36.16 | $258.72K | 338,904 |
| Erin Pennock Foff Chief Medical Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −7,845 | $37.04 | $290.58K | 331,059 |
| Erin Pennock Foff Chief Medical Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −8,972 | $36.99 | $331.87K | 317,622 |
| Erin Pennock Foff Chief Medical Officer | Jul 15, 2026 | Sale(10b5-1 plan) | −4,465 | $36.00 | $160.74K | 326,594 |
| Timothy John Garnett Director | Jun 23, 2026 | Award | +3,932 | – | – | 53,457 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Erin Pennock Foff Officer | Oct 15, 2026 | 15,355 | $119.92K | Oct 15, 2026 | Restricted Stock Unit Grant |
| Christopher A. Kroeger Officer | Oct 15, 2026 | 73,691 | $575.53K | Oct 15, 2026 | Restricted Stock Unit Grant |
| James Woodruff Lillie Officer | Oct 15, 2026 | 11,513 | $89.92K | Oct 15, 2026 | Restricted Stock Unit Grant |
| Malenka Robert Director | Oct 15, 2026 | 14,809 | $115.66K | Oct 15, 2026 | Restricted Stock Units |
| Kreitzer Anatol Officer | Oct 15, 2026 | 12,500 | $97.63K | Oct 15, 2026 | Restricted stock unit settlement |
| Kristopher Hanson Officer | Oct 15, 2026 | 9,020 | $70.45K | Oct 15, 2026 | Restricted Stock Unit Grant |
| Jonathan Gillis Officer | Oct 15, 2026 | 10,167 | $79.40K | Oct 15, 2026 | Restricted Stock Unit Grant |
| Kristopher Hanson Officer | Sep 16, 2026 | 16,509 | $199.43K | Sep 16, 2026 | Vested RSU |
| James Woodruff Lillie Officer | Aug 3, 2026 | 22,082 | $287.51K | Aug 3, 2026 | Vested RSU |
| Holdings A/S Novo Former Affiliate | Jul 30, 2026 | 1,600,000 | $24.03M | Jul 30, 2026 | Direct Investment |
| Kreitzer Anatol Officer | Jul 17, 2026 | 17,173 | $639.18K | Jul 17, 2026 | Restricted Stock Units |
| Gillis Jonathan Officer | Jul 17, 2026 | 18,469 | $687.42K | Jul 17, 2026 | Restricted Stock Units |
| Christopher A. Kroeger Officer | Jul 15, 2026 | 152,230 | $5.77M | Jul 15, 2026 | Restricted Stock Unit Grant |
| Malenka Robert Director | Jul 15, 2026 | 17,537 | $664.83K | Jul 15, 2026 | Restricted Stock Units |
| Erin Pennock Foff Officer | Jul 15, 2026 | 48,158 | $1.83M | Jul 15, 2026 | Restricted Stock Unit Grant |